Australië - Engels - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

department of agriculture, fisheries and forestry - inactivated avian influenza virus type a, h5n2 - misc. vaccines or anti sera - inactivated avian influenza virus type a, h5n2 vaccine active 0.0 undefined - immunotherapy - poultry | breeders | broiler | chickens | chicks | chooks | day old chicks | hatchlings | layers - avian influenza h5 | h5 | virus veterinary

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine adeno virus type 2; canine distemper virus; canine parainfluenza type 2; canine parvo virus - misc. vaccines or anti sera - canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus vaccine-viral active 0.0 p; canine parainfluenza type 2 vaccine-viral active 0.0 p; canine parvo virus vaccine-viral active 0.0 p - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 2 | canine distemper | canine parainfluenza | canine parvovirus | parvovirus

Ierland - Engels - HPRA (Health Products Regulatory Authority)

gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.

Europese Unie - Engels - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance

Europese Unie - Engels - EMA (European Medicines Agency)

gsk vaccines s.r.l. - outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254), recombinant neisseria meningitidis group b fhbp fusion protein, recombinant neisseria meningitidis group b nada protein, recombinant neisseria meningitidis group b nhba fusion protein - meningitis, meningococcal - meningococcal vaccines - active immunisation against invasive disease caused by neisseria meningitidis serogroup-b strains.,

Europese Unie - Engels - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccines - prophylaxis of influenza caused by a(h1n1)v 2009 virus.celvapan should be used in accordance with official guidance.

Europese Unie - Engels - EMA (European Medicines Agency)

sanofi pasteur s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

Europese Unie - Engels - EMA (European Medicines Agency)

intervet international bv - inactivated whole avian influenza virus antigen of h5n2 subtype (strain a/duck/potsdam/1402/86) - immunologicals for aves - chicken - for active immunisation of chickens against avian influenza type a, subtype h5.efficacy has been evaluated on the basis of preliminary results in chickens. reduction of clinical signs, mortality and excretion of virus after challenge were shown by three weeks after vaccination.serum antibodies could be expected to persist for at least 12 months after administration of two doses of vaccine.